Letrozol Cinfa

Letrozole, the active ingredient in Letrozol Cinfa, is an aromatase inhibitor presented as an oral tablet for oral use. It acts by selective non‑steroidal inhibition of the aromatase enzyme, decreasing peripheral estrogen synthesis, and is employed in the endocrine therapy of estrogen receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and global markets.

Letrozol Cinfa, an aromatase inhibitor, is used in the management of estrogen‑driven breast cancer.

- Early‑stage estrogen receptor‑positive breast cancer (adjuvant): reduces recurrence risk. - Metastatic estrogen receptor‑positive breast cancer (first‑line): delays disease progression. - Hormone‑responsive breast cancer in postmenopausal women: provides endocrine control.

Letrozol Cinfa may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: arthralgia or myalgia without clear injury. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Headache: tension‑type or migraine‑like pain. - Dizziness: light‑headed sensation, especially when standing.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated transaminases. - Osteoporotic fractures: increased risk of bone breakage. - Pulmonary embolism or deep‑vein thrombosis: sudden chest pain or leg swelling. - Severe allergic reaction: rash, swelling, difficulty breathing. - Hypercholesterolemia: significant rise in blood cholesterol levels. - Cardiovascular events: hypertension or cardiac ischemia.

Before initiating Letrozol Cinfa, clinicians should consider several safety measures.

- Monitor bone mineral density: risk of osteoporosis and fractures. - Assess liver function: potential hepatotoxicity requires periodic testing. - Evaluate cardiovascular risk: lipid profile changes may occur. - Contraindicated in pregnancy: teratogenic potential. - Ineffective in premenopausal women: low estrogen levels limit benefit. - Store at room temperature: keep below 25°C, protect from moisture and direct sunlight.

Letrozol Cinfa can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Concomitant estrogen therapy: antagonizes letrozole’s aromatase inhibition. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations. - Tamoxifen: opposing mechanisms can diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole exposure. - Warfarin: letrozole can potentiate anticoagulant effect, requiring INR monitoring. - Statins: possible increased risk of myopathy when combined.